Antonio Aitoro
Chief Executive Officer
About GenomSys
The open standard for the genome
GenomSys is a Swiss genomic software company founded with the goal of transforming the way genomic data is stored, processed, shared and used in clinical practice and research. The company operates in the computational genomics and precision medicine segment, developing technologies based on the international standard ISO/IEC 23092 MPEG-G, the first and only ISO standard dedicated to the representation of genomic data.
History
GenomSys was founded in 2016 at EPFL by a group of computer engineers and bioinformaticians with a clear vision: to make genomic data interoperable, secure and easy to use, overcoming the limitations of traditional FASTQ, BAM and VCF formats.
From its inception, the company chose a strategy different from that of most genomics companies. Rather than developing analysis tools exclusively, it invested in building the technological infrastructure intended to become the foundation of future digital genomics.
The most significant outcome of this journey was the company's decisive contribution to the development of the international standard ISO/IEC 23092 MPEG-G, published in 2020 and now recognized as the leading open standard for genomic data management. GenomSys was one of the industrial protagonists in defining the standard and continues to develop its software implementations.
In 2024 the company embarked on a major industrial reorganization, establishing GenomSys S.r.l. in Italy and setting up its MPEG-G Competence Center in Milan, dedicated to software development, bioinformatics and international technical support. At the same time, the management team, the software platform and the commercial strategy were all renewed, with the aim of returning the company to a growth phase focused on the industrial adoption of the MPEG-G standard. The Italian subsidiary is today the center of gravity for design, software production and the commercialization of solutions at both the national and international level.
- 2016
Founded
Engineers and bioinformaticians come together with one goal — bring open standards to genomics.
- 2018
ISO/IEC 23092 drafting
GenomSys leads the technical drafting of what will become the MPEG‑G genomic standard inside ISO/IEC SC 29.
- 2020
MPEG‑G published
The first open international standard for genomic data is published as ISO/IEC 23092 — a joint MPEG and ISO/TC 276 (Biotechnology) effort.
- 2022
MPEG‑G Suite + GVD
The GenomSys MPEG‑G Suite and the GenomSys Variant Discovery platform ship to clinical and research partners.
- 2023
GenomSafe
The companion mobile app launches: encrypted personal genome on device, analyses on demand.
- 2024
MPEG‑G Competence Center
GenomSys establishes the MPEG‑G Competence Center in Milan, expanding its engineering and research footprint.
- 2025
Joint Labs with IIT
Applied research on next-gen compression and graph-genome representation moves into the Joint Labs with Istituto Italiano di Tecnologia.
- 2026
MENA expansion
Distribution agreement signed in Jordan, opening MPEG‑G adoption across the Middle East and North Africa.
The Genomics Market
The genomics sector is undergoing a phase of structural transformation.
Several factors are accelerating demand:
- the spread of personalized medicine
- declining sequencing costs
- national genomic screening programs
- the use of artificial intelligence in medicine
- growth in oncological genomics
- the development of pharmacogenomics
- the expansion of biobanks
All of these phenomena generate enormous volumes of data. Efficient genomic data management is becoming as strategically important as data generation itself. It is precisely at this stage of the value chain that GenomSys operates.
GenomSys's business activity is entirely focused on genomics software.
The company develops a modular platform that enables diagnostic laboratories, hospitals, research centers and biotech companies to manage large volumes of genomic data more efficiently than with traditional technologies.
The Value Proposition
GenomSys's competitive advantage lies not only in software development but, above all, in possessing unique expertise across the entire MPEG-G ecosystem. The standard introduces features not available in traditional genomic formats:
- advanced lossless compression
- selective data access
- genomic data streaming
- full interoperability
- metadata integration
- granular access control
- built-in encryption
These capabilities are built for the increasingly large genomic datasets set to grow further with the spread of next-generation sequencing (NGS).
Outlook
The company's industrial outlook is closely tied to the progressive adoption of the MPEG-G standard.
In the medium term, the market could evolve from a model based on proprietary formats toward a standardized infrastructure.
In this scenario, GenomSys occupies a particularly attractive position, since it:
- contributed to defining the standard
- holds the leading industrial implementation
- possesses highly specialized expertise that is difficult to replicate
- offers a comprehensive platform covering compression, storage, processing and analysis
The company is also expanding its international presence through distribution agreements and industrial partnerships, as well as through participation in major international scientific events dedicated to genomics.
Strategic Vision
The vision stated by management is to build the reference digital infrastructure for the genomics of the future.
The ambition is to do for genomic data what the PDF format has represented for electronic documents: a universal, interoperable standard, independent of individual software vendors.
In this light, GenomSys positions itself not merely as an application developer, but as the technological enabler of the entire precision medicine ecosystem, providing a platform on which hospitals, laboratories, diagnostic companies and developers can build new genomic applications.
One data type at a time
A universal standard for the genome
- JPEG Images
- MP3 Audio
- PDF Documents
- MPEG‑G The genome
Overall Assessment
Chief Executive Officer, GenomSys
From an industrial standpoint, GenomSys holds a distinctive position: rather than competing primarily in the biological interpretation of genomic data, it commands the infrastructural layer of the value chain, developing technologies for the standardized, efficient and secure management of genomic information.
The company's vision is based on the growing adoption of MPEG-G in the coming years. As a result, the company stands to benefit from a competitive advantage derived from the experience gained in developing the standard, from the availability of an already operational proprietary platform, and from its ability to offer interoperable solutions for research, diagnostics and precision medicine.
A multidisciplinary team
Guido Walter Di Donato
Fractional CTO
Sebastiano Bianca
Chief Scientific Officer
Alessandro La Conca
Head of SW Development
Juri Sacchetta
Head of Engineering & Security
Giulio Saulle
Full Stack Developer
Piergiuseppe Quarato
Bioinformatician
Antonino Costantino
Software Developer
Antonio Sgarlata
Software Developer & KAM
Carlo Chiodaroli
Software Developer
Where we are Rooted in Italy,
Rooted in Italy,
worldwide active
GenomSys is parented by GenomSys SA (parent company) in Lugano, Switzerland, and operates in Italy through GenomSys S.r.l. — with sites in Lombardy running research, engineering and the MPEG‑G Competence Center.
From Italy we work with hospitals, research institutes and industrial partners across Europe and beyond.
Lugano
GenomSys SA (parent company)
Via Pietro Peri 6 — 6900 Lugano (TI), Switzerland Monza
Headquarters
Via Antonio Gambacorti Passerini 2 — 20900 Monza Milan
MPEG‑G Competence Center
Via Filippino Lippi 32 — 20131 Milano Investors Backed by shareholders who
Backed by shareholders who
share the vision
A focused group of single-family offices, business angels, and strategic industrial partners — investing in the long-term mission of an open, interoperable genomic stack.
Romed SpA
Single-family office (founded 1985) managing liquid investments across FX, equity, bonds, and venture commitments.
Club degli Investitori
Italy's most active business-angel network — 170+ members, 25-company portfolio, €16M invested since 2008.
Elysia Capital
Single Family Office (Buono-Lopera family, London / Turin) investing in sustainable innovation, education, well-being, arts and culture.
Diagnóstica Longwood
In-vitro diagnostics & research products for immunology, transplant, genetics, hematology, oncology and blood banks.
HandsOnGen
R&D and consulting firm combining operational excellence with cross-disciplinary innovation.
Quality & Compliance
Built to clinical standards
GenomSys operates an integrated management system certified across four international standards. Our quality, security, privacy and medical-device processes are independently audited — a foundation for working in clinical environments and with sensitive genomic data.
ISO 9001:2015
Quality Management Systems
The international benchmark for quality management — the way we plan, deliver and continuously improve everything we ship.
ISO/IEC 27001:2022
Information Security Management
Our information security management system is independently certified to ISO/IEC 27001 — covering risk, controls, and continuous monitoring.
ISO/IEC 27701:2019
Privacy Information Management
An extension of 27001 that adds GDPR-aligned privacy controls — how we handle personal data, including genomic data, end-to-end.
ISO 13485:2016
Medical Devices Quality Management
The international standard for medical-device software. Our applications meet the demands of clinical environments and the regulatory rigour that comes with them.